Drug intelligence / Profile preview

MER683

Development stage: Preclinical
Lead developer: Merida Biosciences

Overview

MER683 is a biologic therapeutic candidate being developed by Merida Biosciences for the treatment of primary membranous nephropathy (pMN). It is designed to clear pathogenic autoantibodies that target the phospholipase A2 receptor (PLA2R), which are the primary drivers of glomerular damage in this autoimmune kidney disease. By specifically removing these autoantibodies from the circulation, MER683 aims to halt the progression of podocyte injury and promote renal recovery. The program is currently in the IND-enabling stage of development.

Targets

PLA2R1 (Phospholipase A2 receptor 1)

Beyond the preview

Go deeper on MER683.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MER683.

Explore the full profile